374 related articles for article (PubMed ID: 32525013)
1. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.
Youssef A; Clark JR; Koschinsky ML; Boffa MB
Trends Cardiovasc Med; 2021 Jul; 31(5):305-311. PubMed ID: 32525013
[TBL] [Abstract][Full Text] [Related]
2. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
Boffa MB; Koschinsky ML
Nat Rev Cardiol; 2019 May; 16(5):305-318. PubMed ID: 30675027
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions.
Lan NSR; Khan Z; Watts GF
Curr Opin Clin Nutr Metab Care; 2024 Jan; 27(1):77-86. PubMed ID: 37650693
[TBL] [Abstract][Full Text] [Related]
4. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
Hung MY; Tsimikas S
Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.
Yeang C; Wilkinson MJ; Tsimikas S
Curr Opin Cardiol; 2016 Jul; 31(4):440-50. PubMed ID: 27205885
[TBL] [Abstract][Full Text] [Related]
6. The current landscape of lipoprotein(a) in calcific aortic valvular disease.
Hsieh G; Rizk T; Berman AN; Biery DW; Blankstein R
Curr Opin Cardiol; 2021 Sep; 36(5):542-548. PubMed ID: 34397461
[TBL] [Abstract][Full Text] [Related]
7. New Frontiers in Lp(a)-Targeted Therapies.
Borrelli MJ; Youssef A; Boffa MB; Koschinsky ML
Trends Pharmacol Sci; 2019 Mar; 40(3):212-225. PubMed ID: 30732864
[TBL] [Abstract][Full Text] [Related]
8. Pathobiology of Lp(a) in calcific aortic valve disease.
Mathieu P; Arsenault BJ; Boulanger MC; Bossé Y; Koschinsky ML
Expert Rev Cardiovasc Ther; 2017 Oct; 15(10):797-807. PubMed ID: 28816078
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis.
Schnitzler JG; Ali L; Groenen AG; Kaiser Y; Kroon J
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31766423
[TBL] [Abstract][Full Text] [Related]
10. In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.
van der Ven CF; Wu PJ; Tibbitt MW; van Mil A; Sluijter JP; Langer R; Aikawa E
Clin Sci (Lond); 2017 Feb; 131(3):181-195. PubMed ID: 28057890
[TBL] [Abstract][Full Text] [Related]
11. COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification.
Vieceli Dalla Sega F; Fortini F; Cimaglia P; Marracino L; Tonet E; Antonucci A; Moscarelli M; Campo G; Rizzo P; Ferrari R
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255450
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease.
Cho KI; Sakuma I; Sohn IS; Jo SH; Koh KK
Atherosclerosis; 2018 Oct; 277():60-65. PubMed ID: 30173080
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve.
Bouchareb R; Mahmut A; Nsaibia MJ; Boulanger MC; Dahou A; Lépine JL; Laflamme MH; Hadji F; Couture C; Trahan S; Pagé S; Bossé Y; Pibarot P; Scipione CA; Romagnuolo R; Koschinsky ML; Arsenault BJ; Marette A; Mathieu P
Circulation; 2015 Aug; 132(8):677-90. PubMed ID: 26224810
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.
Thanassoulis G
J Lipid Res; 2016 Jun; 57(6):917-24. PubMed ID: 26685327
[TBL] [Abstract][Full Text] [Related]
15. Bone Morphogenetic Protein Signaling Is Required for Aortic Valve Calcification.
Gomez-Stallons MV; Wirrig-Schwendeman EE; Hassel KR; Conway SJ; Yutzey KE
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1398-405. PubMed ID: 27199449
[TBL] [Abstract][Full Text] [Related]
16. Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.
Tsimikas S
Circ Res; 2019 Feb; 124(3):405-415. PubMed ID: 30702993
[TBL] [Abstract][Full Text] [Related]
17. Calcific Aortic Valve Disease: Part 1--Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks.
Pasipoularides A
J Cardiovasc Transl Res; 2016 Apr; 9(2):102-18. PubMed ID: 26891845
[TBL] [Abstract][Full Text] [Related]
18. The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?
Boffa MB; Koschinsky ML
Curr Opin Lipidol; 2018 Jun; 29(3):259-267. PubMed ID: 29528858
[TBL] [Abstract][Full Text] [Related]
19. Metformin alleviates the calcification of aortic valve interstitial cells through activating the PI3K/AKT pathway in an AMPK dependent way.
En Q; Zeping H; Yuetang W; Xu W; Wei W
Mol Med; 2021 Dec; 27(1):156. PubMed ID: 34895136
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.
Mahmut A; Boulanger MC; El Husseini D; Fournier D; Bouchareb R; Després JP; Pibarot P; Bossé Y; Mathieu P
J Am Coll Cardiol; 2014 Feb; 63(5):460-9. PubMed ID: 24161325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
